Boston Financial Mangement LLC Invests $50,000 in ASP Isotopes Inc. (NASDAQ:ASPI)

Boston Financial Mangement LLC bought a new position in ASP Isotopes Inc. (NASDAQ:ASPI) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 11,000 shares of the company’s stock, valued at approximately $50,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Hanson & Doremus Investment Management purchased a new stake in ASP Isotopes in the fourth quarter worth approximately $27,000. B. Riley Wealth Advisors Inc. purchased a new stake in ASP Isotopes in the third quarter worth approximately $42,000. The Manufacturers Life Insurance Company purchased a new stake in ASP Isotopes in the third quarter worth approximately $52,000. JPMorgan Chase & Co. boosted its stake in ASP Isotopes by 31.4% in the third quarter. JPMorgan Chase & Co. now owns 22,196 shares of the company’s stock worth $62,000 after buying an additional 5,307 shares in the last quarter. Finally, KKM Financial LLC boosted its stake in ASP Isotopes by 66.2% in the third quarter. KKM Financial LLC now owns 22,600 shares of the company’s stock worth $63,000 after buying an additional 9,000 shares in the last quarter. Hedge funds and other institutional investors own 16.80% of the company’s stock.

ASP Isotopes Stock Down 2.6 %

Shares of ASPI opened at $4.78 on Friday. The firm has a market cap of $340.89 million, a P/E ratio of -7.83 and a beta of 3.51. The stock has a 50 day simple moving average of $5.30 and a two-hundred day simple moving average of $4.55. The company has a debt-to-equity ratio of 0.80, a current ratio of 7.55 and a quick ratio of 7.54. ASP Isotopes Inc. has a 1 year low of $1.86 and a 1 year high of $9.33.

ASP Isotopes Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.